Biogen Inc.
BIIB | NASDAQ
$249.39
-$4.23 (-1.67%)
Nov 2, 2026, 12:04 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 9.81B | 9.68B | 9.84B | 10.17B | 10.98B | 13.44B |
Cost of Revenue | 2.9B | 2.31B | 2.53B | 2.28B | 2.11B | 1.81B |
Gross Profit | 6.91B | 7.37B | 7.3B | 7.9B | 8.87B | 11.64B |
Operating Income | 1.88B | 2.49B | 2.1B | 2.89B | 2.79B | 4.59B |
Interest Income | 87.8M | 67.6M | 276.5M | 89.3M | 11M | 42M |
Pretax Income | 1.4B | 1.91B | 1.3B | 3.59B | 1.78B | 5.05B |
Net Income | 1.29B | 1.63B | 1.16B | 3.05B | 1.56B | 4B |
Selling & General & Admin | 2.43B | 2.39B | 2.5B | 2.41B | 2.68B | 2.52B |
Research & Development | 1.95B | 2.49B | 2.7B | 2.6B | 3.4B | 4.53B |
Other Expenses | 647.7M | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 5.04B | 4.88B | 5.2B | 5.01B | 6.08B | 7.05B |
Interest Expense | 246M | 250.3M | 246.9M | 246.6M | 253.6M | 222.5M |
Selling & Marketing Expenses | n/a | 66.8M | 71.4M | 54.1M | 98.7M | 111.8M |
Cost & Expenses | 7.93B | 7.19B | 7.74B | 7.28B | 8.19B | 8.85B |
Income Tax Expense | 108.11M | 273.8M | 135.3M | 632.8M | 52.5M | 992.3M |
Shares Outstanding (Basic) | 146.7M | 145.7M | 144.7M | 145.3M | 149.1M | 160.9M |
Shares Outstanding (Diluted) | 146.7M | 145.9M | 145.6M | 146M | 149.6M | 161.3M |
EPS (Basic) | 8.85 | 11.20 | 8.02 | 20.97 | 10.44 | 24.86 |
EPS (Diluted) | 8.83 | 11.19 | 7.97 | 20.87 | 10.40 | 24.80 |
EBITDA | 2.95B | 3B | 2.38B | 3.54B | 3.92B | 5.11B |
EBIT | 2.17B | 2.32B | 1.88B | 3.02B | 3.44B | 4.65B |
Depreciation & Amortization | 779.9M | 673.2M | 494.8M | 518.4M | 487.7M | 457.2M |
Add to Watchlist
Select watchlists to add or remove BIIB